Skip to content

De-resuscitation Informed by Ultrasound for Patients With Sepsis

Optimizing Fluid Management Informed by Ultrasound for Patients With Sepsis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04921319
Acronym
DRI-US
Enrollment
152
Registered
2021-06-10
Start date
2021-04-26
Completion date
2022-07-30
Last updated
2021-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Sepsis, Severe, Septic Shock, Volume Overload

Brief summary

Randomized, unblinded clinical trial of 152 critically ill patients with sepsis admitted to the intensive care unit. The primary determine if using the Venous Excess Ultrasound Score (VExUS) to guide fluid deresuscitation in critically ill patients with sepsis reduces net fluid balance at 5 days as compared to usual care.

Detailed description

Physicians can assess venous congestions with point of care ultrasound of intraabdominal veins using the venous excess in ultrasound score (VExUS), which has been shown to predict the harmful effects of volume overload. We seek to determine if VExUS-guided deresuscitation reduces the fluid balance in critically ill patients with sepsis as compared to usual care. This score compiles findings from the inferior vena cava, hepatic vein Doppler waveform, portal vein Doppler waveform, and intrarenal vein Doppler waveform: Grade 0: IVC \< 2cm, normal pattern in flow patterns of hepatic, portal, and intrarenal veins Grade 1: IVC ≥ 2cm, normal patterns or mild abnormalities in flow patterns of hepatic, portal, and intrarenal veins. Grade 2: IVC ≥ 2cm, severe venous flow pattern in one among hepatic, portal, and intrarenal veins. Grade 3: IVC ≥ 2cm, severe venous flow pattern in multiple among hepatic, portal, and intrarenal veins. After informed consent, subjects will be randomized in a 1:1 ratio to the VExUS-guided intervention arm vs control arm. Subjects in both arms will undergo daily ultrasound, and the investigator will calculate the VExUS immediately after ultrasounds are obtained.

Interventions

DIAGNOSTIC_TESTVExUS score

The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows: * VExUS 0: The patient will likely tolerate more fluid if clinically needed. * VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis. * VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day.

Sponsors

The Miriam Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized, unblinded clinical trial of 152 critically ill patients with sepsis admitted to the intensive care unit.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. Must be suspected by the treating physician to have sepsis as the primary cause of their acute illness as exhibited by 2 or more of the following Systemic Inflammatory Response Syndrome (SIRS) criteria: 1. Temperature of \> 38 C or \< 36 C 2. Heart rate of \> 90/min 3. Respiratory rate of \> 20/min or PaCO2 \< 32 mm Hg 4. White blood cell count \> 12000/mm3 or \< 4000/mm3 or \>10% immature bands. 2. Known or suspected infection at the time of screening 3. Admission to the ICU for \<24 hours Since approximately 12% of patients ultimately diagnosed with sepsis do not meet SIRS criteria, SIRS negative patients will be eligible for the study if the treating physician makes a clinical diagnosis of severe sepsis or septic shock.

Exclusion criteria

1. Patients with conditions that may interfere with portal Doppler assessments such as cirrhosis or portal thrombosis 2. Patients with severe chronic kidney disease (estimated glomerular filtration rate\<15 mL/min per 1.73 m2 calculated using the Modified Diet in Renal Disease formula). 3. Age \< 18 years 4. Active atrial fibrillation or atrial flutter 5. Hemodynamic instability due to active hemorrhage 6. Acute cerebral vascular event 7. Acute coronary syndrome (excluding elevated troponin thought to be from demand ischemia) 8. Acute pulmonary edema 9. Status asthmaticus 10. Drug overdose 11. Injury from burn or trauma 12. Status epilepticus 13. Indication for immediate surgery 14. Received CPR within 24 hours of enrollment 15. Pregnancy 16. Incarceration.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative Fluid Balance at 5 days post ICU discharge or ICU DischargeAt 5 days post ICU admission or ICU discharge, whichever comes firstTotal fluid balance (ins minus outs)

Secondary

MeasureTime frameDescription
Incidence of respiratory failureAt 5 days post ICU admission or ICU discharge, whichever comes firstIncidence of respiratory failure defined by intubation rates, ventilator free days, ventilator days, use of non-invasive positive pressure ventilation, and use of high flow oxygen
Change in SOFA scoreAt 5 days post ICU admission or ICU discharge, whichever comes firstChange in Sequential Organ Failure Assessment (SOFA) score during study period, on scale of 0-48, with higher values being a worse outcome
Incidence of Acute Kidney InjuryAt 5 days post ICU admission or ICU discharge, whichever comes firstacute kidney injury as defined by KDIGO criteria
ICU discharge fluid balanceFrom ICU admission to ICU discharge or 30 days after ICU admission, whichever comes firstCumulative admission fluid balance at time of ICU discharge.
Daily Sonographic B Line Measurementstudy enrollment to ICU discharge or 5 days post-enrollment, whichever comes firstMeasured by counting sonographic B lines in 16 lung zones
28-day and in-hospital mortality28 days and during hospital admission up to 24 weeksAll-cause mortality.

Countries

United States

Contacts

Primary ContactChristopher F Allison, MD
callison@lifespan.org401-793-4501

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026